Tag Archives: United States Patent and Trademark Office

USPTO Issues New Myriad Guidance

Kaylee_dna_115x76

On Tuesday, December 16 the United States Patent and Trademark Office issued a revised guidance on subject matter eligibility under § 101 in light of recent Supreme Court Decisions in Alice v. CLS Bank, Mayo, and Myriad. These new guidelines are a response to extensive feedback provided from industry leaders and inventors over the last several months. (BIO provided both initial and supplemental comments on the Office’s March Subject Matter Eligibility Guidance). Public comments on the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

BIO Submits Comments on “Myriad” PTO Patent Guidance

Supreme Court - Phil Roeder

On July 31st, BIO, alongside a group of international bioindustry trade associations submitted comments to the United States Patent and Trademark Office regarding their March 4, 2014 Guidance on patent subject matter eligibility. Representing associations from Japan, Australia, Canada, the UK, Germany, Spain, Portugal Belgium, the Netherlands and others, the comments reflect a deep concern among the international community regarding how the PTO is interpreting the Supreme Court’s recent decisions in Mayo v. Prometheus and Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Exclusive Licenses Do Not Discourage Follow On Research

medical_research_thumb

A recent study presented at the Patent Statistics for Decision Makers Conference organized at the United States Patent Office questions the logic behind a nonexclusive license preference often found in U.S. government technology transfer policy. In “The Role of Exclusive Licensing in Follow-on Research of Academic Patented Inventions” presentation the authors demonstrate that, contrary to the belief by some, exclusive licensing does not impede future research. The authors ask two questions.  First, does exclusive licensing affect licensee follow-on research?  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

IPCC Features Update on Patent Reform Implementation

Gongola_Janet

The BIO Intellectual Property Counsels Committee Fall Conference featured an update on the implementation of the Leahy-Smith America Invents Act by Janet Gongola, Associate Solicitor of the U.S. Patent and Trademark Office (PTO). Some provisions of the Leahy-Smith America Invents Act took effect immediately when it was signed into law in September. Ms. Gongola reported that of the 20 provisions that must be implemented by the PTO, eight have been implemented and another ten are Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Celebrating 30 Years of Biotechnology Innovation: From Diamond v. Chakrabarty to Today

Kappos-200

David Kappos, Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO), provided opening remarks at an event entitled, Celebrating 30 years of Biotechnology Innovation: From Diamond v. Chakrabarty to Today during the 2011 BIO International Convention. The forum, co-sponsored by the US Patent and Trademark Office, The Biotechnology Industry Organization and the Biojudiciary Project, celebrated the 30th anniversary of the issuance of the patent from the Supreme Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,